8-K: Lyell Immunopharma Announces Positive Initial Clinical Data for IMPT-314 in B-cell Lymphoma

Lyell Immunopharma reported a 94% objective response rate and a 71% complete response rate in a Phase 1-2 trial of IMPT-314 for large B-cell lymphoma.

Summary

• Lyell Immunopharma presented initial positive clinical data from its Phase 1-2 trial of IMPT-314, a dual-targeting CAR T-cell therapy, at the 2024 ASH Annual Meeting.
• The study involved 23 patients with relapsed or refractory large B-cell lymphoma who had not previously received CAR T-cell therapy.
• The efficacy evaluable population consisted of 17 patients, with a 94% objective response rate (ORR), meaning 16 out of 17 patients showed tumor shrinkage.
• A complete response (CR) rate of 71% was achieved, with 12 out of 17 patients showing no detectable cancer after treatment.
• The median follow-up time was 6.3 months, and 71% of patients were still in response at their last follow-up.
• The safety profile was manageable, with no high-grade cytokine release syndrome (CRS) reported.
• Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 13% of patients, but resolved quickly with standard treatment.
• IMPT-314 demonstrated robust expansion in patients, with peak cell expansion occurring between days 7 and 28 post-infusion.
• The final drug product contained a high proportion of naive and central memory T cells, which are associated with improved survival in other CAR T-cell studies.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with high response rates and a manageable safety profile, suggesting a promising outlook for the therapy. The planned pivotal trial further boosts confidence. However, the risks associated with clinical trials and the need for additional capital temper the sentiment slightly.

Positives

• The high objective and complete response rates suggest strong efficacy of IMPT-314.
• The manageable safety profile, with no high-grade CRS, is a significant advantage.
• The rapid resolution of ICANS with standard treatment is encouraging.
• The robust expansion and favorable T-cell phenotype of IMPT-314 are positive indicators.
• The consistency with prior UCLA trial data provides further validation.
• The planned pivotal trial in 2025 indicates confidence in the therapy's potential.

Negatives

• Grade 3 ICANS was observed in 13% of patients, although it was manageable.
• The median follow-up of 6.3 months is relatively short, and longer-term data is needed to assess durability of response.

Risks

• The company has limited experience in enrolling and completing clinical trials.
• There is a risk that the nonclinical profiles of the product candidates may not translate into clinical trials.
• Clinical trial results may differ from nonclinical, early clinical, preliminary or expected results.
• There is a risk of significant adverse events, toxicities or other undesirable side effects.
• The company may not be able to obtain regulatory approvals for its product candidates.
• The company may need additional capital to achieve its goals.
• The company is subject to macroeconomic conditions, including geopolitical instability and changes in interest rates and inflation.

Future Outlook

Lyell plans to initiate a pivotal trial of IMPT-314 in 2025 for CAR T-naive patients with large B-cell lymphoma in the 3rd-line+ setting and is continuing to evaluate IMPT-314 in the 2nd-line setting in the ongoing Phase 1-2 trial.

Management Comments

• Lynn Seely, M.D., Lyell's President and Chief Executive Officer, stated that the data supports the strong potential of IMPT-314.
• Sarah M. Larson, M.D., from UCLA, noted that the IMPT-314 data is consistent with their experience with CART19/20 and suggests the potential for differentiated benefit over first-generation CD19 CAR therapies.

Industry Context

This announcement is significant in the CAR T-cell therapy space, as it presents a next-generation dual-targeting approach that aims to improve upon existing CD19-targeted therapies. The results suggest a potential advancement in the treatment of aggressive B-cell lymphomas, a competitive area with several approved CAR T-cell therapies.

Comparison to Industry Standards

• The reported 94% ORR and 71% CR are very competitive compared to existing CD19-targeted CAR T-cell therapies such as Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel), which have shown ORRs in the 50-80% range and CRs in the 40-60% range in similar patient populations.
• The manageable safety profile, particularly the absence of high-grade CRS, is a notable advantage over some first-generation CAR T-cell therapies, which are known to have higher rates of severe CRS and ICANS.
• The use of a dual-targeting approach (CD19 and CD20) is a strategy to overcome antigen escape, a known limitation of single-target CAR T-cell therapies.
• The enrichment for naive and central memory T cells is also a key differentiator, as these cell types are associated with improved persistence and long-term efficacy, which is a major focus in the field.
• The consistency with the UCLA trial of CART19/20, which uses the same CAR construct, provides further validation of the approach.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and the potential for a new treatment option.
• Patients with large B-cell lymphoma may benefit from this new therapy if it proves successful in larger trials.
• Employees of Lyell may be motivated by the positive results and the potential for the company's growth.
• The medical community will be interested in the data and the potential for a new treatment paradigm.

Next Steps

• Lyell plans to initiate a pivotal trial of IMPT-314 in 2025 for CAR T-naive patients with large B-cell lymphoma in the 3rd-line+ setting.
• The company will continue to evaluate IMPT-314 in the 2nd-line setting in the ongoing Phase 1-2 trial.

Key Dates

Keywords

IMPT-314, CAR T-cell therapy, B-cell lymphoma, CD19, CD20, Hematologic malignancies, Clinical trial, Objective response rate, Complete response rate, Cytokine release syndrome, Neurotoxicity, ASH Annual Meeting